GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, Chief Scientific Officer
“Michael brings a broad range of expertise that spans drug development, biomarker discovery and diagnostic development and commercialization, along with a strong track record developing and executing R&D strategies that built significant value,” said Dr. Myla Lai-Goldman, CEO/Co-Founder of GeneCentric. “We look forward to his R&D leadership as GeneCentric grows its portfolio of cancer profilers based on high resolution genomic subtyping and expands its range of relationships with pharmaceutical partners.”
In his role as CSO of GeneCentric, Dr. Milburn will lead the company’s efforts to advance and expand its portfolio of Cancer Profilers to identify drug responders based on its proprietary Cancer Subtyping Platform (CSP®). He will also play an integral role in overseeing and building our collaborations with pharmaceutical and academic partners. The company currently has Cancer Profilers for lung and head and neck cancer, bladder and pancreatic cancer, as well as a growing pipeline of Profilers in other cancers including multiple myeloma.
Previously, Dr. Milburn joined Metabolon in 2005 as one of the first scientists recruited into the company and led the development of its core metabolomic technology and the growth of its R&D organization. In addition to overseeing R&D, he played an integral role in establishing high value scientific and commercial partnerships. Prior to Metabolon, he served as Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals and Senior Vice President of Research at Plexxikon. He also held senior research positions at Structural Genomix (VP of Structural Biology); and GlaxoWellcome (Department Head of Structural Chemistry).
Dr. Milburn holds a BS in Chemistry (with highest honors) from the University of Michigan and a PhD in Biophysical Chemistry from the University of California at Berkeley.
About GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our initial approach applies our Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we are defining responder populations based on subtypes throughout the drug development cycle. For more information, please visit www.GeneCentric.com.
GeneCentric Therapeutics, Inc.
Walter M. Capone, 984-329-3837
Chief Business Officer
Source: GeneCentric Therapeutics, Inc.